Pharsight

Boehringer Ingelheim patents expiration

1. Aggrenox patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6015577 BOEHRINGER INGELHEIM Pharmaceutical compositions containing dipyridamole or mopidamol and acetylsalicylic acid or the physiologically acceptable salts thereof, processes for preparing them and their use in treating clot formation
Jan, 2017

(7 years ago)

Drugs and Companies using ASPIRIN; DIPYRIDAMOLE ingredient

Market Authorisation Date: 22 November, 1999

Treatment: To reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of AGGRENOX before it's drug patent expiration?
More Information on Dosage

AGGRENOX family patents

Family Patents

2. Aptivus patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6169181 BOEHRINGER INGELHEIM Compounds useful to treat retroviral infections
May, 2014

(9 years ago)

US5852195 BOEHRINGER INGELHEIM Pyranone compounds useful to treat retroviral infections
Jun, 2019

(4 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6169181

(Pediatric)

BOEHRINGER INGELHEIM Compounds useful to treat retroviral infections
Nov, 2014

(9 years ago)

US6231887 BOEHRINGER INGELHEIM Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation
Jul, 2018

(5 years ago)

US6231887

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation
Jan, 2019

(5 years ago)

US6147095 BOEHRINGER INGELHEIM Method for improving the pharmacokinetics of tipranavir
Oct, 2019

(4 years ago)

US5852195

(Pediatric)

BOEHRINGER INGELHEIM Pyranone compounds useful to treat retroviral infections
Dec, 2019

(4 years ago)

US6147095

(Pediatric)

BOEHRINGER INGELHEIM Method for improving the pharmacokinetics of tipranavir
Apr, 2020

(3 years ago)

Drug Exclusivity Drug Exclusivity Expiration
Pediatric Exclusivity(PED) Dec 23, 2011

Drugs and Companies using TIPRANAVIR ingredient

Market Authorisation Date: 23 June, 2008

Treatment: Treatment of hiv-1 infection by the co-administration of tipranavir and ritonavir.

Dosage: SOLUTION;ORAL; CAPSULE;ORAL

More Information on Dosage

APTIVUS family patents

Family Patents

3. Atrovent Hfa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5676930 BOEHRINGER INGELHEIM Stabilized medicinal aerosol solution formulations
Oct, 2014

(9 years ago)

US5683677 BOEHRINGER INGELHEIM Medicinal aerosol formulations
Nov, 2014

(9 years ago)

US6983743 BOEHRINGER INGELHEIM Stainless steel canister for propellant-driven metering aerosols
May, 2020

(3 years ago)

US6739333 BOEHRINGER INGELHEIM Stainless steel canister for propellant-driven metering aerosols
May, 2020

(3 years ago)

US8474447 BOEHRINGER INGELHEIM Inhaler device
Jan, 2030

(5 years from now)

Drugs and Companies using IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 27 November, 2004

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

ATROVENT HFA family patents

Family Patents

4. Combivent patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5603918 BOEHRINGER INGELHEIM Aerosol composition of a salt of ipratropium and a salt of albuterol
Jun, 2015

(8 years ago)

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 24 October, 1996

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

COMBIVENT family patents

Family Patents

5. Combivent Respimat patents expiration

COMBIVENT RESPIMAT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5497944 BOEHRINGER INGELHEIM Atomising devices and methods
Mar, 2013

(11 years ago)

US5472143 BOEHRINGER INGELHEIM Atomising nozzle and filter and spray generation device
Sep, 2013

(10 years ago)

US6503362 BOEHRINGER INGELHEIM Atomizing nozzle an filter and spray generating device
Sep, 2013

(10 years ago)

US5911851 BOEHRINGER INGELHEIM Atomizing nozzle and filter and spray generating device
Sep, 2013

(10 years ago)

US6007676 BOEHRINGER INGELHEIM Atomizing nozzle and filter and spray generating device
Sep, 2013

(10 years ago)

US5662271 BOEHRINGER INGELHEIM Atomizing devices and methods
Sep, 2014

(9 years ago)

US7246615 BOEHRINGER INGELHEIM Atomising nozzle and filter and spray generating device
May, 2016

(7 years ago)

US6176442 BOEHRINGER INGELHEIM Device for mounting a component exposed to a pressurized fluid
Oct, 2016

(7 years ago)

US7104470 BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Oct, 2016

(7 years ago)

US6726124 BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Oct, 2016

(7 years ago)

US5964416 BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Oct, 2016

(7 years ago)

US6453795 BOEHRINGER INGELHEIM Locking mechanism for a spring-actuated device
Dec, 2016

(7 years ago)

US6149054 BOEHRINGER INGELHEIM Mechanical counter for a metering apparatus
Dec, 2016

(7 years ago)

US6846413 BOEHRINGER INGELHEIM Microstructured filter
Aug, 2018

(5 years ago)

US6977042 BOEHRINGER INGELHEIM Microstructured filter
Aug, 2018

(5 years ago)

US7802568 BOEHRINGER INGELHEIM Cartridge for a liquid
Feb, 2019

(5 years ago)

US6988496 BOEHRINGER INGELHEIM Cartridge for a liquid
Feb, 2020

(4 years ago)

US7988001 BOEHRINGER INGELHEIM Container provided with a pressure equalization opening
Aug, 2021

(2 years ago)

US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(4 months from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(1 year, 1 month from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Oct, 2026

(2 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2027

(2 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2028

(3 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Oct, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 07, 2014

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 07 October, 2011

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

How can I launch a generic of COMBIVENT RESPIMAT before it's drug patent expiration?
More Information on Dosage

COMBIVENT RESPIMAT family patents

Family Patents

6. Gilotrif patents expiration

GILOTRIF's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6251912 BOEHRINGER INGELHEIM Substituted quinazoline derivatives
Jul, 2018

(5 years ago)

USRE43431 BOEHRINGER INGELHEIM Quinazoline derivatives and pharmaceutical compositions containing them
Jan, 2026

(1 year, 8 months from now)

US8426586 BOEHRINGER INGELHEIM Process for preparing amino crotonyl compounds
Oct, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43431

(Pediatric)

BOEHRINGER INGELHEIM Quinazoline derivatives and pharmaceutical compositions containing them
Jul, 2026

(2 years from now)

US9539258 BOEHRINGER INGELHEIM Quinazoline derivatives for the treatment of cancer diseases
Nov, 2026

(2 years from now)

US9539258

(Pediatric)

BOEHRINGER INGELHEIM Quinazoline derivatives for the treatment of cancer diseases
May, 2027

(3 years from now)

US8545884 BOEHRINGER INGELHEIM Solid pharmaceutical formulations comprising BIBW 2992
Dec, 2029

(5 years from now)

US8426586

(Pediatric)

BOEHRINGER INGELHEIM Process for preparing amino crotonyl compounds
Apr, 2030

(5 years from now)

US8545884

(Pediatric)

BOEHRINGER INGELHEIM Solid pharmaceutical formulations comprising BIBW 2992
Jun, 2030

(6 years from now)

US10004743 BOEHRINGER INGELHEIM Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
Jul, 2030

(6 years from now)

US10004743

(Pediatric)

BOEHRINGER INGELHEIM Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
Jan, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-230) Jan 12, 2025
M(M-276) Apr 07, 2025
Pediatric Exclusivity(PED) Oct 07, 2025
Orphan Drug Exclusivity(ODE) Apr 15, 2023
New Chemical Entity Exclusivity(NCE) Jul 12, 2018
New Indication(I-730) Apr 15, 2019
Orphan Drug Exclusivity(ODE-115) Apr 15, 2023
New Indication(I-763) Jan 12, 2021
Orphan Drug Exclusivity(ODE-50) Jul 12, 2020

Drugs and Companies using AFATINIB DIMALEATE ingredient

NCE-1 date: 07 October, 2024

Market Authorisation Date: 12 July, 2013

Treatment: Treatment of patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy; Treatment of cancer

Dosage: TABLET;ORAL

How can I launch a generic of GILOTRIF before it's drug patent expiration?
More Information on Dosage

GILOTRIF family patents

Family Patents

7. Glyxambi patents expiration

GLYXAMBI's oppositions filed in EPO
GLYXAMBI Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(1 year, 11 days from now)

US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(2 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6303661 BOEHRINGER INGELHEIM Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(6 years ago)

US6890898 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7078381 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7459428 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(8 months ago)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(8 months ago)

US7407955

(Pediatric)

BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Nov, 2025

(1 year, 6 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(1 year, 7 months from now)

US8883805

(Pediatric)

BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
May, 2026

(2 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(3 years from now)

US11033552 BOEHRINGER INGELHEIM DPP IV inhibitor formulations
May, 2027

(3 years from now)

US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors
May, 2027

(3 years from now)

US7713938

(Pediatric)

BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Oct, 2027

(3 years from now)

US8673927

(Pediatric)

BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
Nov, 2027

(3 years from now)

US11033552

(Pediatric)

BOEHRINGER INGELHEIM DPP IV inhibitor formulations
Nov, 2027

(3 years from now)

US7579449

(Pediatric)

BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Feb, 2029

(4 years from now)

US8551957 BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Oct, 2029

(5 years from now)

US8551957

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Apr, 2030

(5 years from now)

US8846695 BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Jun, 2030

(6 years from now)

US10406172 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2030

(6 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11833166 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(10 years from now)

US10258637

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Oct, 2034

(10 years from now)

US11090323

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Oct, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-739) Dec 02, 2019
New Combination(NC) Jan 30, 2018
M(M-258) Jul 03, 2022
New Chemical Entity Exclusivity(NCE) Aug 01, 2019
M(M-252) Mar 30, 2023

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

NCE-1 date: 01 August, 2018

Market Authorisation Date: 30 January, 2015

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with...

Dosage: TABLET;ORAL

How can I launch a generic of GLYXAMBI before it's drug patent expiration?
More Information on Dosage

GLYXAMBI family patents

Family Patents

8. Jardiance patents expiration

JARDIANCE's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(2 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7713938

(Pediatric)

BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Oct, 2027

(3 years from now)

US7579449

(Pediatric)

BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Feb, 2029

(4 years from now)

US8551957 BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Oct, 2029

(5 years from now)

US8551957

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Apr, 2030

(5 years from now)

US10406172 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2030

(6 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11666590 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11833166 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11813275 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US9949997 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
May, 2034

(10 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(10 years from now)

US10258637

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Oct, 2034

(10 years from now)

US11090323

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Oct, 2034

(10 years from now)

US9949997

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Nov, 2034

(10 years from now)

US9949998

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Dec, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 20, 2026
New Indication(I-869) Aug 18, 2024
New Indication(I-922) Sep 21, 2026
M(M-82) Feb 24, 2025
Pediatric Exclusivity(PED) Dec 20, 2026
M(M-159) Jun 26, 2018
New Indication(I-739) Dec 02, 2019
New Chemical Entity Exclusivity(NCE) Aug 01, 2019
M(M-160) Jun 26, 2018
M(M-161) Jun 26, 2018
M(M-174) Mar 18, 2019

Drugs and Companies using EMPAGLIFLOZIN ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 01 August, 2014

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with...

Dosage: TABLET;ORAL

How can I launch a generic of JARDIANCE before it's drug patent expiration?
More Information on Dosage

JARDIANCE family patents

Family Patents

9. Jentadueto patents expiration

JENTADUETO's oppositions filed in EPO
JENTADUETO Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(1 year, 11 days from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6303661 BOEHRINGER INGELHEIM Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(6 years ago)

US7459428 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US6890898 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7078381 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(8 months ago)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(8 months ago)

US7407955

(Pediatric)

BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Nov, 2025

(1 year, 6 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(1 year, 7 months from now)

US8883805

(Pediatric)

BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
May, 2026

(2 years from now)

US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors
May, 2027

(3 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(3 years from now)

US8673927

(Pediatric)

BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
Nov, 2027

(3 years from now)

US10973827 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(4 years from now)

US10022379 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(4 years from now)

US9415016 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(4 years from now)

US10022379

(Pediatric)

BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Oct, 2029

(5 years from now)

US9415016

(Pediatric)

BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Oct, 2029

(5 years from now)

US10973827

(Pediatric)

BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Oct, 2029

(5 years from now)

US9155705 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
May, 2030

(6 years from now)

US8846695 BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Jun, 2030

(6 years from now)

US9155705

(Pediatric)

BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Nov, 2030

(6 years from now)

US8846695

(Pediatric)

BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Dec, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-295) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026
M(M-146) Jul 30, 2017
M(M-252) Mar 30, 2023
M(M-258) Jul 03, 2022
New Combination(NC) Jan 30, 2015
New Chemical Entity Exclusivity(NCE) May 02, 2016

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 30 January, 2012

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in com...

Dosage: TABLET;ORAL

How can I launch a generic of JENTADUETO before it's drug patent expiration?
More Information on Dosage

JENTADUETO family patents

Family Patents

10. Jentadueto Xr patents expiration

JENTADUETO XR's oppositions filed in EPO
JENTADUETO XR Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(1 year, 11 days from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6635280 BOEHRINGER INGELHEIM Extending the duration of drug release within the stomach during the fed mode
Sep, 2016

(7 years ago)

US6340475 BOEHRINGER INGELHEIM Extending the duration of drug release within the stomach during the fed mode
Sep, 2016

(7 years ago)

US6303661 BOEHRINGER INGELHEIM Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(6 years ago)

US7459428 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US6890898 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7078381 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US6488962 BOEHRINGER INGELHEIM Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
Jun, 2020

(3 years ago)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(8 months ago)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(8 months ago)

US7407955

(Pediatric)

BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Nov, 2025

(1 year, 6 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(1 year, 7 months from now)

US8883805

(Pediatric)

BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
May, 2026

(2 years from now)

US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors
May, 2027

(3 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(3 years from now)

US8673927

(Pediatric)

BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
Nov, 2027

(3 years from now)

US9173859

(Pediatric)

BOEHRINGER INGELHEIM Uses of DPP IV inhibitors
Nov, 2027

(3 years from now)

US10022379 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(4 years from now)

US9415016 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(4 years from now)

US10022379

(Pediatric)

BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Oct, 2029

(5 years from now)

US9415016

(Pediatric)

BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Oct, 2029

(5 years from now)

US9155705 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
May, 2030

(6 years from now)

US8846695 BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Jun, 2030

(6 years from now)

US9155705

(Pediatric)

BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Nov, 2030

(6 years from now)

US9555001 BOEHRINGER INGELHEIM Pharmaceutical composition and uses thereof
Mar, 2033

(8 years from now)

US9555001

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition and uses thereof
Sep, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-295) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026
M(M-252) Mar 30, 2023
M(M-258) Jul 03, 2022

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 May, 2016

Treatment: Method of treating type 2 diabetes; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering a dip...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of JENTADUETO XR before it's drug patent expiration?
More Information on Dosage

JENTADUETO XR family patents

Family Patents

11. Micardis patents expiration

MICARDIS's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5591762 BOEHRINGER INGELHEIM Benzimidazoles useful as angiotensin-11 antagonists
Jan, 2014

(10 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5591762 BOEHRINGER INGELHEIM Benzimidazoles useful as angiotensin-11 antagonists
Jan, 2014

(10 years ago)

US6358986 BOEHRINGER INGELHEIM Polymorphs of telmisartan
Jan, 2020

(4 years ago)

US7998953 BOEHRINGER INGELHEIM Use of inhibitors of the renin-angiotensin system
Jun, 2020

(3 years ago)

US8003679 BOEHRINGER INGELHEIM Use of inhibitors of the renin-angiotensin system
Oct, 2022

(1 year, 6 months ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-612) Oct 16, 2012

Drugs and Companies using TELMISARTAN ingredient

Market Authorisation Date: 04 April, 2000

Treatment: Treatment of hypertension; Reduction of cardiac tissue damage associated with myocardial infarction; Treatment or prevention of stroke

Dosage: TABLET;ORAL

How can I launch a generic of MICARDIS before it's drug patent expiration?
More Information on Dosage

MICARDIS family patents

Family Patents

12. Micardis Hct patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5591762 BOEHRINGER INGELHEIM Benzimidazoles useful as angiotensin-11 antagonists
Jan, 2014

(10 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6358986 BOEHRINGER INGELHEIM Polymorphs of telmisartan
Jan, 2020

(4 years ago)

Drugs and Companies using HYDROCHLOROTHIAZIDE; TELMISARTAN ingredient

Market Authorisation Date: 17 November, 2000

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

How can I launch a generic of MICARDIS HCT before it's drug patent expiration?
More Information on Dosage

MICARDIS HCT family patents

Family Patents

13. Mirapex patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6194445 BOEHRINGER INGELHEIM Use of pramipexole in the treatment of restless legs syndrome
Jan, 2018

(6 years ago)

US6001861 BOEHRINGER INGELHEIM Use of pramipexole in the treatment of restless legs syndrome
Jan, 2018

(6 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-104) May 13, 2014

Drugs and Companies using PRAMIPEXOLE DIHYDROCHLORIDE ingredient

Market Authorisation Date: 01 July, 1997

Treatment: Treatment of moderate to severe primary restless legs syndrome (rls)

Dosage: TABLET;ORAL

How can I launch a generic of MIRAPEX before it's drug patent expiration?
More Information on Dosage

MIRAPEX family patents

Family Patents

14. Mirapex Er patents expiration

MIRAPEX ER's oppositions filed in EPO
MIRAPEX ER Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7695734 BOEHRINGER INGELHEIM Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
Apr, 2028

(4 years from now)

US8679533 BOEHRINGER INGELHEIM Pramipexole once-daily dosage form
Sep, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-623) Mar 19, 2013
New Dosage Form(NDF) Feb 19, 2013

Drugs and Companies using PRAMIPEXOLE DIHYDROCHLORIDE ingredient

Market Authorisation Date: 19 February, 2010

Treatment: Treatment of parkinson's disease

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of MIRAPEX ER before it's drug patent expiration?
More Information on Dosage

MIRAPEX ER family patents

Family Patents

15. Ofev patents expiration

OFEV's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7119093 BOEHRINGER INGELHEIM 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
Feb, 2024

(a month ago)

US6762180 BOEHRINGER INGELHEIM Substituted indolines which inhibit receptor tyrosine kinases
Oct, 2025

(1 year, 5 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7989474 BOEHRINGER INGELHEIM Use of Lck inhibitors for treatment of immunologic diseases
Apr, 2024

(14 days ago)

US10154990 BOEHRINGER INGELHEIM Medicaments for the treatment or prevention of fibrotic diseases
Jan, 2026

(1 year, 8 months from now)

US6762180

(Pediatric)

BOEHRINGER INGELHEIM Substituted indolines which inhibit receptor tyrosine kinases
Apr, 2026

(1 year, 11 months from now)

US10154990

(Pediatric)

BOEHRINGER INGELHEIM Medicaments for the treatment or prevention of fibrotic diseases
Jul, 2026

(2 years from now)

US10105323 BOEHRINGER INGELHEIM Pharmaceutical dosage form for immediate release of an indolinone derivative
Jun, 2029

(5 years from now)

US9907756 BOEHRINGER INGELHEIM Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
Jun, 2029

(5 years from now)

US10105323

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical dosage form for immediate release of an indolinone derivative
Dec, 2029

(5 years from now)

US9907756

(Pediatric)

BOEHRINGER INGELHEIM Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
Dec, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-261) Sep 06, 2026
Pediatric Exclusivity(PED) Mar 06, 2027
New Indication(I-805) Sep 06, 2022
Orphan Drug Exclusivity(ODE) Oct 15, 2021
New Chemical Entity Exclusivity(NCE) Oct 15, 2019
New Indication(I-825) Mar 09, 2023
Orphan Drug Exclusivity(ODE-77) Oct 15, 2021

Drugs and Companies using NINTEDANIB ESYLATE ingredient

NCE-1 date: 06 March, 2026

Market Authorisation Date: 15 October, 2014

Treatment: Treatment of idiopathic pulmonary fibrosis (ipf); Use of nintedanib for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-...

Dosage: CAPSULE;ORAL

How can I launch a generic of OFEV before it's drug patent expiration?
More Information on Dosage

OFEV family patents

Family Patents

16. Pradaxa patents expiration

PRADAXA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6087380 BOEHRINGER INGELHEIM Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
Dec, 2021

(2 years ago)

US7932273 BOEHRINGER INGELHEIM 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament
Sep, 2025

(1 year, 4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6087380

(Pediatric)

BOEHRINGER INGELHEIM Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
Jun, 2022

(1 year, 9 months ago)

US9925174 BOEHRINGER INGELHEIM Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof
Jun, 2023

(10 months ago)

US9925174

(Pediatric)

BOEHRINGER INGELHEIM Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof
Dec, 2023

(4 months ago)

US7932273

(Pediatric)

BOEHRINGER INGELHEIM 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament
Mar, 2026

(1 year, 10 months from now)

US7866474 BOEHRINGER INGELHEIM Film container
Aug, 2027

(3 years from now)

US7866474

(Pediatric)

BOEHRINGER INGELHEIM Film container
Mar, 2028

(3 years from now)

US9034822 BOEHRINGER INGELHEIM Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds
Jan, 2031

(6 years from now)

US9034822

(Pediatric)

BOEHRINGER INGELHEIM Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds
Jul, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jun 21, 2024
Pediatric Exclusivity(PED) Dec 21, 2024

Drugs and Companies using DABIGATRAN ETEXILATE MESYLATE ingredient

Market Authorisation Date: 21 June, 2021

Treatment: Method of reversing the anticoagulant effect of dabigatran using idarucizumab; Treatment of venous thrombotic disease

Dosage: PELLETS;ORAL; CAPSULE;ORAL

How can I launch a generic of PRADAXA before it's drug patent expiration?
More Information on Dosage

PRADAXA family patents

Family Patents

17. Spiriva patents expiration

SPIRIVA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE39820 BOEHRINGER INGELHEIM Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
Jan, 2018

(6 years ago)

US7642268 BOEHRINGER INGELHEIM Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
Sep, 2021

(2 years ago)

US6908928 BOEHRINGER INGELHEIM Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
Sep, 2021

(2 years ago)

US7309707 BOEHRINGER INGELHEIM Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
Sep, 2021

(2 years ago)

US6777423 BOEHRINGER INGELHEIM Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
Sep, 2021

(2 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5478578 BOEHRINGER INGELHEIM Powders for inhalation
Dec, 2012

(11 years ago)

USRE39820

(Pediatric)

BOEHRINGER INGELHEIM Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
Jul, 2018

(5 years ago)

USRE38912 BOEHRINGER INGELHEIM Process for preparing powder formulations
Oct, 2021

(2 years ago)

US7070800 BOEHRINGER INGELHEIM Inhalable powder containing tiotropium
Jan, 2022

(2 years ago)

US7642268

(Pediatric)

BOEHRINGER INGELHEIM Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
Mar, 2022

(2 years ago)

US7309707

(Pediatric)

BOEHRINGER INGELHEIM Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
Mar, 2022

(2 years ago)

US6777423

(Pediatric)

BOEHRINGER INGELHEIM Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
Mar, 2022

(2 years ago)

US6908928

(Pediatric)

BOEHRINGER INGELHEIM Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
Mar, 2022

(2 years ago)

USRE38912

(Pediatric)

BOEHRINGER INGELHEIM Process for preparing powder formulations
Apr, 2022

(2 years ago)

US7070800

(Pediatric)

BOEHRINGER INGELHEIM Inhalable powder containing tiotropium
Jul, 2022

(1 year, 8 months ago)

US8022082 BOEHRINGER INGELHEIM Method for the administration of an anticholinergic by inhalation
Jan, 2026

(1 year, 8 months from now)

US8022082

(Pediatric)

BOEHRINGER INGELHEIM Method for the administration of an anticholinergic by inhalation
Jul, 2026

(2 years from now)

US7694676 BOEHRINGER INGELHEIM Dry powder inhaler
Mar, 2027

(2 years from now)

US7694676

(Pediatric)

BOEHRINGER INGELHEIM Dry powder inhaler
Sep, 2027

(3 years from now)

US9010323 BOEHRINGER INGELHEIM Inhaler and sieve for an inhaler
Apr, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-89) Dec 17, 2012

Drugs and Companies using TIOTROPIUM BROMIDE ingredient

Market Authorisation Date: 30 January, 2004

Treatment: For the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema; Administration of an inha...

Dosage: POWDER;INHALATION

How can I launch a generic of SPIRIVA before it's drug patent expiration?
More Information on Dosage

SPIRIVA family patents

Family Patents

18. Spiriva Respimat patents expiration

SPIRIVA RESPIMAT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE39820 BOEHRINGER INGELHEIM Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
Jan, 2018

(6 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6176442 BOEHRINGER INGELHEIM Device for mounting a component exposed to a pressurized fluid
May, 2016

(7 years ago)

US6176242 BOEHRINGER INGELHEIM Method of treating manic depression by brain infusion
May, 2016

(7 years ago)

US7246615 BOEHRINGER INGELHEIM Atomising nozzle and filter and spray generating device
May, 2016

(7 years ago)

US7104470 BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Oct, 2016

(7 years ago)

US5964416 BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Oct, 2016

(7 years ago)

US6726124 BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Oct, 2016

(7 years ago)

US7246615

(Pediatric)

BOEHRINGER INGELHEIM Atomising nozzle and filter and spray generating device
Dec, 2016

(7 years ago)

US6176442

(Pediatric)

BOEHRINGER INGELHEIM Device for mounting a component exposed to a pressurized fluid
Dec, 2016

(7 years ago)

US6453795 BOEHRINGER INGELHEIM Locking mechanism for a spring-actuated device
Dec, 2016

(7 years ago)

US6149054 BOEHRINGER INGELHEIM Mechanical counter for a metering apparatus
Dec, 2016

(7 years ago)

US6726124

(Pediatric)

BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Apr, 2017

(7 years ago)

US7104470

(Pediatric)

BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Apr, 2017

(7 years ago)

US5964416

(Pediatric)

BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Apr, 2017

(7 years ago)

US6453795

(Pediatric)

BOEHRINGER INGELHEIM Locking mechanism for a spring-actuated device
Jun, 2017

(6 years ago)

US6149054

(Pediatric)

BOEHRINGER INGELHEIM Mechanical counter for a metering apparatus
Jun, 2017

(6 years ago)

USRE39820

(Pediatric)

BOEHRINGER INGELHEIM Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
Jul, 2018

(5 years ago)

US6846413 BOEHRINGER INGELHEIM Microstructured filter
Aug, 2018

(5 years ago)

US6977042 BOEHRINGER INGELHEIM Microstructured filter
Aug, 2018

(5 years ago)

US7802568 BOEHRINGER INGELHEIM Cartridge for a liquid
Feb, 2019

(5 years ago)

US6846413

(Pediatric)

BOEHRINGER INGELHEIM Microstructured filter
Feb, 2019

(5 years ago)

US6977042

(Pediatric)

BOEHRINGER INGELHEIM Microstructured filter
Feb, 2019

(5 years ago)

US7802568

(Pediatric)

BOEHRINGER INGELHEIM Cartridge for a liquid
Aug, 2019

(4 years ago)

US6988496 BOEHRINGER INGELHEIM Cartridge for a liquid
Feb, 2020

(4 years ago)

US6988496

(Pediatric)

BOEHRINGER INGELHEIM Cartridge for a liquid
Aug, 2020

(3 years ago)

US7988001 BOEHRINGER INGELHEIM Container provided with a pressure equalization opening
Aug, 2021

(2 years ago)

US7988001

(Pediatric)

BOEHRINGER INGELHEIM Container provided with a pressure equalization opening
Feb, 2022

(2 years ago)

US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(4 months from now)

US7284474

(Pediatric)

BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Feb, 2025

(10 months from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(1 year, 1 month from now)

US7896264

(Pediatric)

BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
Nov, 2025

(1 year, 7 months from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Oct, 2026

(2 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2027

(2 years from now)

US7396341

(Pediatric)

BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Apr, 2027

(2 years from now)

US9027967

(Pediatric)

BOEHRINGER INGELHEIM Device for clamping a fluidic component
Oct, 2027

(3 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2028

(3 years from now)

US7837235

(Pediatric)

BOEHRINGER INGELHEIM Device for clamping a fluidic component
Sep, 2028

(4 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Oct, 2030

(6 years from now)

US8733341

(Pediatric)

BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Apr, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 24, 2017
New Patient Population(NPP) Feb 15, 2020
Pediatric Exclusivity(PED) Aug 15, 2020

Drugs and Companies using TIOTROPIUM BROMIDE ingredient

Market Authorisation Date: 15 September, 2015

Treatment: Maintenance treatment of bronchospasm associated with copd, including chronic bronchitis and emphysema, and reduction of exacerbations in copd patients.

Dosage: SPRAY, METERED;INHALATION

How can I launch a generic of SPIRIVA RESPIMAT before it's drug patent expiration?
More Information on Dosage

SPIRIVA RESPIMAT family patents

Family Patents

19. Stiolto Respimat patents expiration

STIOLTO RESPIMAT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE39820 BOEHRINGER INGELHEIM Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
Jan, 2018

(6 years ago)

US7491719 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments
Nov, 2023

(5 months ago)

US7056916 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Dec, 2023

(4 months ago)

US7220742 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(1 year, 21 days from now)

US7727984 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Jan, 2027

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7246615 BOEHRINGER INGELHEIM Atomising nozzle and filter and spray generating device
May, 2016

(7 years ago)

US7104470 BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Oct, 2016

(7 years ago)

US6726124 BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Oct, 2016

(7 years ago)

US6176442 BOEHRINGER INGELHEIM Device for mounting a component exposed to a pressurized fluid
Oct, 2016

(7 years ago)

US5964416 BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Oct, 2016

(7 years ago)

US6453795 BOEHRINGER INGELHEIM Locking mechanism for a spring-actuated device
Dec, 2016

(7 years ago)

US6149054 BOEHRINGER INGELHEIM Mechanical counter for a metering apparatus
Dec, 2016

(7 years ago)

US6149054

(Pediatric)

BOEHRINGER INGELHEIM Mechanical counter for a metering apparatus
Jun, 2017

(6 years ago)

US6846413 BOEHRINGER INGELHEIM Microstructured filter
Aug, 2018

(5 years ago)

US6977042 BOEHRINGER INGELHEIM Microstructured filter
Aug, 2018

(5 years ago)

US7802568 BOEHRINGER INGELHEIM Cartridge for a liquid
Feb, 2019

(5 years ago)

US6977042

(Pediatric)

BOEHRINGER INGELHEIM Microstructured filter
Feb, 2019

(5 years ago)

US6846413

(Pediatric)

BOEHRINGER INGELHEIM Microstructured filter
Feb, 2019

(5 years ago)

US7802568

(Pediatric)

BOEHRINGER INGELHEIM Cartridge for a liquid
Aug, 2019

(4 years ago)

US6988496 BOEHRINGER INGELHEIM Cartridge for a liquid
Feb, 2020

(4 years ago)

US6988496

(Pediatric)

BOEHRINGER INGELHEIM Cartridge for a liquid
Aug, 2020

(3 years ago)

US7988001 BOEHRINGER INGELHEIM Container provided with a pressure equalization opening
Aug, 2021

(2 years ago)

US7786111 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Nov, 2023

(5 months ago)

US8044046 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Nov, 2023

(5 months ago)

US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(4 months from now)

US7284474

(Pediatric)

BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Feb, 2025

(10 months from now)

US8034809 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(1 year, 21 days from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(1 year, 1 month from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Oct, 2026

(2 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2027

(2 years from now)

US7396341

(Pediatric)

BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Apr, 2027

(2 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2028

(3 years from now)

US7837235

(Pediatric)

BOEHRINGER INGELHEIM Device for clamping a fluidic component
Sep, 2028

(4 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Oct, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-233) Oct 05, 2021
New Combination(NC) May 21, 2018
New Chemical Entity Exclusivity(NCE) Jul 31, 2019
M(M-173) Mar 18, 2019

Drugs and Companies using OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE ingredient

NCE-1 date: 31 July, 2018

Market Authorisation Date: 21 May, 2015

Treatment: Treatment of copd; Treatment of respiratory complaints

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage

STIOLTO RESPIMAT family patents

Family Patents

20. Striverdi Respimat patents expiration

STRIVERDI RESPIMAT's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7491719 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof, and use thereof as medicaments
Nov, 2023

(5 months ago)

US7056916 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Dec, 2023

(4 months ago)

US7220742 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(1 year, 21 days from now)

US7727984 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Jan, 2027

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7246615 BOEHRINGER INGELHEIM Atomising nozzle and filter and spray generating device
May, 2016

(7 years ago)

US6726124 BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Oct, 2016

(7 years ago)

US7104470 BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Oct, 2016

(7 years ago)

US5964416 BOEHRINGER INGELHEIM Device for producing high pressure in a fluid in miniature
Oct, 2016

(7 years ago)

US6176442 BOEHRINGER INGELHEIM Device for mounting a component exposed to a pressurized fluid
Oct, 2016

(7 years ago)

US6453795 BOEHRINGER INGELHEIM Locking mechanism for a spring-actuated device
Dec, 2016

(7 years ago)

US6149054 BOEHRINGER INGELHEIM Mechanical counter for a metering apparatus
Dec, 2016

(7 years ago)

US6846413 BOEHRINGER INGELHEIM Microstructured filter
Aug, 2018

(5 years ago)

US6977042 BOEHRINGER INGELHEIM Microstructured filter
Aug, 2018

(5 years ago)

US7802568 BOEHRINGER INGELHEIM Cartridge for a liquid
Feb, 2019

(5 years ago)

US6988496 BOEHRINGER INGELHEIM Cartridge for a liquid
Feb, 2020

(4 years ago)

US7988001 BOEHRINGER INGELHEIM Container provided with a pressure equalization opening
Aug, 2021

(2 years ago)

US8044046 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Nov, 2023

(5 months ago)

US7786111 BOEHRINGER INGELHEIM Medicaments for the treatment of chronic obstructive pulmonary disease
Nov, 2023

(5 months ago)

US7284474 BOEHRINGER INGELHEIM Piston-pumping system having o-ring seal properties
Aug, 2024

(4 months from now)

US8034809 BOEHRINGER INGELHEIM Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
May, 2025

(1 year, 21 days from now)

US7896264 BOEHRINGER INGELHEIM Microstructured high pressure nozzle with built-in filter function
May, 2025

(1 year, 1 month from now)

US7396341 BOEHRINGER INGELHEIM Blocking device for a locking stressing mechanism having a spring-actuated output drive device
Oct, 2026

(2 years from now)

US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2027

(2 years from now)

US7837235 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2028

(3 years from now)

US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Oct, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 31, 2019

Drugs and Companies using OLODATEROL HYDROCHLORIDE ingredient

NCE-1 date: 31 July, 2018

Market Authorisation Date: 31 July, 2014

Treatment: Treatment of chronic obstructive pulmonary disease (copd), chronic bronchitis or emphysema

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage

STRIVERDI RESPIMAT family patents

Family Patents

21. Synjardy patents expiration

SYNJARDY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(2 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7713938

(Pediatric)

BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Oct, 2027

(3 years from now)

US7579449

(Pediatric)

BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Feb, 2029

(4 years from now)

US10610489 BOEHRINGER INGELHEIM Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
Sep, 2030

(6 years from now)

US10610489

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
Mar, 2031

(6 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11833166 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11813275 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US9949997 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
May, 2034

(10 years from now)

US11090323

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Oct, 2034

(10 years from now)

US10258637

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Oct, 2034

(10 years from now)

US9949997

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Nov, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026
New Indication(I-739) Dec 02, 2019
New Product(NP) Aug 26, 2018
New Chemical Entity Exclusivity(NCE) Aug 01, 2019
M(M-174) Mar 18, 2019

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 26 August, 2015

Treatment: Method of treating type 2 diabetes mellitus in a patent with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation i...

Dosage: TABLET;ORAL

How can I launch a generic of SYNJARDY before it's drug patent expiration?
More Information on Dosage

SYNJARDY family patents

Family Patents

22. Synjardy Xr patents expiration

SYNJARDY XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(2 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6488962 BOEHRINGER INGELHEIM Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
Jun, 2020

(3 years ago)

US7713938

(Pediatric)

BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Oct, 2027

(3 years from now)

US7579449

(Pediatric)

BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Feb, 2029

(4 years from now)

US10596120 BOEHRINGER INGELHEIM Pharmaceutical compositions
Mar, 2032

(7 years from now)

US10596120

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical compositions
Sep, 2032

(8 years from now)

US11813275 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11833166 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US9949997 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
May, 2034

(10 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(10 years from now)

US10258637

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Oct, 2034

(10 years from now)

US11090323

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Oct, 2034

(10 years from now)

US9949997

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Nov, 2034

(10 years from now)

US9949998

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Dec, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-296) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026
New Chemical Entity Exclusivity(NCE) Aug 01, 2019
New Indication(I-739) Dec 02, 2019

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 09 December, 2016

Treatment: Treatment of a treatment-naïve patient with inadequately controlled type 2 diabetes using a composition comprising an extended release core comprising metformin and an outer coating comprising empagli...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of SYNJARDY XR before it's drug patent expiration?
More Information on Dosage

SYNJARDY XR family patents

Family Patents

23. Tradjenta patents expiration

TRADJENTA's oppositions filed in EPO
TRADJENTA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(1 year, 11 days from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6303661 BOEHRINGER INGELHEIM Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Apr, 2017

(6 years ago)

US7459428 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US6890898 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US7078381 BOEHRINGER INGELHEIM Method of regulating glucose metabolism, and reagents related thereto
Feb, 2019

(5 years ago)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(8 months ago)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(8 months ago)

US7407955

(Pediatric)

BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Nov, 2025

(1 year, 6 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(1 year, 7 months from now)

US8883805

(Pediatric)

BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
May, 2026

(2 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(3 years from now)

US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors
May, 2027

(3 years from now)

US11033552 BOEHRINGER INGELHEIM DPP IV inhibitor formulations
May, 2027

(3 years from now)

US11033552

(Pediatric)

BOEHRINGER INGELHEIM DPP IV inhibitor formulations
Nov, 2027

(3 years from now)

US8673927

(Pediatric)

BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
Nov, 2027

(3 years from now)

US9486526 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy
Aug, 2029

(5 years from now)

US10034877 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy
Aug, 2029

(5 years from now)

US10034877

(Pediatric)

BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy
Feb, 2030

(5 years from now)

US9486526

(Pediatric)

BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy
Feb, 2030

(5 years from now)

US8846695 BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Jun, 2030

(6 years from now)

US8846695

(Pediatric)

BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Dec, 2030

(6 years from now)

US8853156 BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy
Mar, 2031

(6 years from now)

US8853156

(Pediatric)

BOEHRINGER INGELHEIM Treatment for diabetes in patients inappropriate for metformin therapy
Sep, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
M(M-295) Jun 20, 2026
Pediatric Exclusivity(PED) Dec 20, 2026
M(M-252) Mar 30, 2023
M(M-258) Jul 03, 2022
M(M-121) Aug 13, 2015
New Chemical Entity Exclusivity(NCE) May 02, 2016
M(M-118) Aug 13, 2015

Drugs and Companies using LINAGLIPTIN ingredient

NCE-1 date: 20 December, 2025

Market Authorisation Date: 02 May, 2011

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor; Method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (...

Dosage: TABLET;ORAL

How can I launch a generic of TRADJENTA before it's drug patent expiration?
More Information on Dosage

TRADJENTA family patents

Family Patents

24. Trijardy Xr patents expiration

TRIJARDY XR's oppositions filed in EPO
TRIJARDY XR Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7407955 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
May, 2025

(1 year, 11 days from now)

US7713938 BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Apr, 2027

(2 years from now)

US7579449 BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Aug, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6488962 BOEHRINGER INGELHEIM Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
Jun, 2020

(3 years ago)

US8119648 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(8 months ago)

US8178541 BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Aug, 2023

(8 months ago)

US7407955

(Pediatric)

BOEHRINGER INGELHEIM 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Nov, 2025

(1 year, 6 months from now)

US8883805 BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
Nov, 2025

(1 year, 7 months from now)

US8883805

(Pediatric)

BOEHRINGER INGELHEIM Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
May, 2026

(2 years from now)

US9173859 BOEHRINGER INGELHEIM Uses of DPP IV inhibitors
May, 2027

(3 years from now)

US8673927 BOEHRINGER INGELHEIM Uses of DPP-IV inhibitors
May, 2027

(3 years from now)

US7713938

(Pediatric)

BOEHRINGER INGELHEIM Crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
Oct, 2027

(3 years from now)

US7579449

(Pediatric)

BOEHRINGER INGELHEIM Glucopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
Feb, 2029

(4 years from now)

US10022379 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(4 years from now)

US9415016 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
Apr, 2029

(4 years from now)

US8551957 BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Oct, 2029

(5 years from now)

US8551957

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
Apr, 2030

(5 years from now)

US9155705 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
May, 2030

(6 years from now)

US10406172 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2030

(6 years from now)

US10596120 BOEHRINGER INGELHEIM Pharmaceutical compositions
Mar, 2032

(7 years from now)

US11564886 BOEHRINGER INGELHEIM Pharmaceutical compositions
Mar, 2032

(7 years from now)

US11090323 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US10258637 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US11833166 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Apr, 2034

(9 years from now)

US9949998 BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Jun, 2034

(10 years from now)

US11090323

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Oct, 2034

(10 years from now)

US10258637

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Oct, 2034

(10 years from now)

US9949998

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical composition, methods for treating and uses thereof
Dec, 2034

(10 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 January, 2020

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin; Method of treating type 2 diabetes using a pharmaceutical composition comprisi...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of TRIJARDY XR before it's drug patent expiration?
More Information on Dosage

TRIJARDY XR family patents

Family Patents

25. Twynsta patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5591762 BOEHRINGER INGELHEIM Benzimidazoles useful as angiotensin-11 antagonists
Jan, 2014

(10 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Oct 16, 2012

Drugs and Companies using AMLODIPINE BESYLATE; TELMISARTAN ingredient

Market Authorisation Date: 16 October, 2009

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

More Information on Dosage

TWYNSTA family patents

Family Patents

26. Viramune Xr patents expiration

VIRAMUNE XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8460704 BOEHRINGER INGELHEIM Extended release formulation of nevirapine
Mar, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Mar 25, 2014
New Patient Population(NPP) Nov 08, 2015

Drugs and Companies using NEVIRAPINE ingredient

Market Authorisation Date: 08 November, 2012

Treatment: Treatment of hiv-1 by once daily administration

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of VIRAMUNE XR before it's drug patent expiration?
More Information on Dosage

VIRAMUNE XR family patents

Family Patents